Clinical trials: Anti-vascular Endothelial Growth Factor
Diabetic Macular Edema, Cataract
Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification
The primary objective of this study is to compare the efficacy of antecedent intravitreal anti-vascular endothelial growth factor therapy vs.
- Trial name
- STAMP (NCT03832179)
- Testing
- Bevacizumab, Ranibizumab, Aflibercept
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bay Area Retina Associates
Diabetic Macular Edema
Anterior and Posterior Segment Vascular Changes Following Laser and Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Diabetic Retinopathy
The study will investigate changes in the structure and function of blood vessels in the front and back of the eye following laser and anti-VEGF treatments for sight-threatening diabetic eye disease.
- Trial name
- VEGF (NCT01196325)
- Where
- Canada
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Neovascular Age Related Macular Degeneration
NVAMD Satellite Study
Intravitreal delivery of anti-vascular endothelial growth factor (VEGF) drugs has revolutionized the management of neovascular age-related macular degeneration (NVAMD).
- Trial name
- NCT02251366
- Testing
- Physician-guided diagnostic
- Where
- 5 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Wet AMD
Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy
To obtain a genotypic analysis of patients with chronic exudative age-related macular degeneration noted to have subretinal or intraretinal edema despite continuous monthly Anti-VEGF therapy.
- Trial name
- NCT01310686
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- West Coast Retina Medical Group, Inc.
Retinal Vein Occlusion, Macular Edema
A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema
This retrospective data review study will evaluate anti-VEGF injections for retinal vein occlusion (RVO) or diabetic macular edema (DME).
- Trial name
- NCT01918371
- Testing
- Anti-VEGF
- Where
- United States
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Allergan
Pain
Intravitreal Injection Site and Perceived Pain
The objective of this study is to explore the perception of pain during intravitreal injection related to the distance of the entry site from the limbus.
- Trial name
- NCT05640895
- Testing
- Intravitreal injection site
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Metastatic Colorectal Cancer, Non Small Cell Lung Cancer Metastatic
Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects
This is a randomized, double-blind, single-dose, parallel-group study comparing pharmacokinetic characteristics, safety , tolerability and immunogenicity of LY01008 (Recombinant Humanized Anti-Human Vascular Endothelial Growth…
- Conditions
- Metastatic Colorectal Cancer, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Recurrent
- Trial name
- NCT05110118
- Testing
- LY01008, Avastin
- Where
- China
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Shandong Boan Biotechnology Co., Ltd
Retinal Vein Occlusion, Macular Edema
Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion
Antagonists of the vascular endothelial growth factor (VEGF) pathway are effective in treating macular edema resulting from retinal vein occlusion (RVO).
- Trial name
- CRAVE (NCT01428388)
- Testing
- Intravitreal injection of bevacizumab, Intravitreal injection of ranibizumab (0.5 mg per dose)
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Barnes Retina Institute
Post-Injection Intraocular Pressure Spikes
Pre-Administration of Brimonidine in Intravitreal Anti-VEGF Therapy
In this study, investigators will be examining the intraocular pressure lowering effect of brimonidine 0.15% when administered 20min prior to intravitreal anti-VEGF injection.
- Trial name
- NCT03513172
- Testing
- topical brimonidine tartrate 0.15% (Alphagan® P; Allergan, Inc)
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Neovascular Age-related Macular Edema, Diabetic Macular Edema
Anti-VEGF in Real-world
Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of…
- Conditions
- Neovascular Age-related Macular Edema, Diabetic Macular Edema, Choroidal Neovascular Membrane, Non-proliferative Diabetic Retinopathy
- Trial name
- NCT05222633
- Testing
- Ranibizumab, Aflibercept, Conbercept
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Wenbin Wei